Agomab Therapeutics (AGMB) Assets Average (2025)
Agomab Therapeutics (AGMB) posted quarterly Assets Average of $199.7 million for Q4 2025.
Agomab Therapeutics (AGMB) Assets Average (2025) Analysis & Trends
Agomab Therapeutics' Assets Average history runs 1 years deep, the most recent figure standing at $199.7 million for Q4 2025.
- In Q4 2025, Assets Average changed N/A year-over-year to $199.7 million; the TTM figure through Dec 2025 stood at $199.7 million (changed N/A YoY), while the FY2025 annual figure was $201.1 million, changed N/A from the prior year.
- Assets Average for Q4 2025 stood at $199.7 million.
- The five-year high for Assets Average was $199.7 million in Q4 2025, with the low at $199.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Agomab Therapeutics | 7.07 Mn | -250.51 Mn | - | 258.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 199.72 Mn |